AU2001285205B2 - Fused pyrrolocarbazoles against inflammation - Google Patents
Fused pyrrolocarbazoles against inflammation Download PDFInfo
- Publication number
- AU2001285205B2 AU2001285205B2 AU2001285205A AU2001285205A AU2001285205B2 AU 2001285205 B2 AU2001285205 B2 AU 2001285205B2 AU 2001285205 A AU2001285205 A AU 2001285205A AU 2001285205 A AU2001285205 A AU 2001285205A AU 2001285205 B2 AU2001285205 B2 AU 2001285205B2
- Authority
- AU
- Australia
- Prior art keywords
- carbons
- alkyl
- compound
- aryl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical class N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 title description 37
- 206010061218 Inflammation Diseases 0.000 title description 9
- 230000004054 inflammatory process Effects 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- -1 2-pyrimidyl Chemical group 0.000 claims description 19
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 230000001575 pathological effect Effects 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 230000002491 angiogenic effect Effects 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000017497 prostate disease Diseases 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000037803 restenosis Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 201000009273 Endometriosis Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000022873 Ocular disease Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 201000002222 hemangioblastoma Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010028537 myelofibrosis Diseases 0.000 claims description 6
- 230000009826 neoplastic cell growth Effects 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 62
- 239000000203 mixture Substances 0.000 description 57
- 230000000694 effects Effects 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 35
- 239000007787 solid Substances 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 29
- 230000001228 trophic effect Effects 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- 230000004083 survival effect Effects 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 108091008605 VEGF receptors Proteins 0.000 description 14
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 102000020233 phosphotransferase Human genes 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 108091008606 PDGF receptors Proteins 0.000 description 12
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 12
- 230000001537 neural effect Effects 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 11
- 229940053128 nerve growth factor Drugs 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 9
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 8
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 239000006196 drop Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 7
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 7
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 7
- 102000003923 Protein Kinase C Human genes 0.000 description 7
- 108090000315 Protein Kinase C Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 210000002932 cholinergic neuron Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 101150025395 trkA gene Proteins 0.000 description 6
- 101150113435 trkA1 gene Proteins 0.000 description 6
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 5
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 5
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 230000001713 cholinergic effect Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 4
- 101710084006 Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 4
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 108010041596 mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000002241 neurite Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010065874 Psoriatic conditions Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- ZODAOVNETBTTJX-UHFFFAOYSA-N bis(4-methoxyphenyl)methanol Chemical compound C1=CC(OC)=CC=C1C(O)C1=CC=C(OC)C=C1 ZODAOVNETBTTJX-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940093495 ethanethiol Drugs 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SURVRMRLLSFWHA-UHFFFAOYSA-N 3-(dimethylazaniumyl)butanoate Chemical compound CN(C)C(C)CC(O)=O SURVRMRLLSFWHA-UHFFFAOYSA-N 0.000 description 1
- PSUXTZLDBVEZTD-UHFFFAOYSA-N 3-bromopropoxymethylbenzene Chemical compound BrCCCOCC1=CC=CC=C1 PSUXTZLDBVEZTD-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 229910003850 O-nPr Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 101001076308 Xenopus laevis Insulin-like growth factor III Proteins 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QILSFLSDHQAZET-UHFFFAOYSA-N diphenylmethanol Chemical group C=1C=CC=CC=1C(O)C1=CC=CC=C1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009518 penetrating injury Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 02/17914 PCT/US01/26266 SELECTED FUSED PYRROLOCARBAZOLES FIELD OF THE INVENTION The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
BACKGROUND OF THE INVENTION Publications cited throughout this disclosure are incorporated in their entirety herein by reference.
Various synthetic small organic molecules that are biologically active and generally known in the art as "fused pyrrolocarbazoles" have been prepared (See U.S.
Patent Nos. 5,475,110; 5,591,855; 5,594,009; and 5,616,724). In addition, U.S. Patent 5,705,511 discloses fused pyrrolocarbazole compounds which possess a variety of functional pharmacological activities. The fused pyrrolocarbazoles were disclosed to be used in a variety of ways, including: enhancing the function and/or survival of cells of neuronal lineage, either singularly or in combination with neurotrophic factor(s) and/or indolocarbozoles; enhancing trophic factor-induced activity; inhibition of protein kinase C activity; inhibition of trk tyrosine kinase activity; inhibition of proliferation of a prostate cancer cell-line; inhibition of the cellular pathways involved in the inflammation process; and enhancement of the survival of neuronal cells at risk of dying.
The present inventors have found that certain selected fused pyrrolocarbazoles selected from the generic formulas of U.S. Patent 5,705,511 but not specifically disclosed therein possess surprising and unexpected biological activities compared to the compounds described in U.S. Patent 5,705,511.
WO 02/17914 PCT/US01/26266 -2- SUMMARY OF THE INVENTION Accordingly, one object of the invention is to provide novel fused pyrrolocarbazole compounds represented by the general Formula I: Formula I Constituent members of Formula I are disclosed in detail, infra.
Preferred fused pyrrolocarbazoles are represented by the following Formula II: Formula II Constituent members of Formula II are disclosed in detail, infra.
The fused pyrrolocarbazoles of the present invention may be used in a variety of ways, including: inhibition of angiogenesis; antitumor agents; enhancing the function and/or survival of cells of neuronal lineage, either singularly or in combination with neurotrophic factor(s) and/or indolocarbozoles; enhancing trophic factor-induced activity; inhibition of kinases; inhibition of vascular endothelial growth factor receptor (VEGFR) kinase, preferably VEGFR2; inhibition of mixed lineage kinase (MLK); trk kinase; inhibition of platelet derived growth factor receptor (PDGFR) kinase; inhibition of NGF-stimulated trk phosphorylation; inhibition of protein kinase C activity; inhibition of trk tyrosine kinase activity; inhibition of proliferation of a prostate cancer cell-line; inhibition of the cellular pathways involved in the inflammation process; and enhancement of the survival of neuronal cells at risk of dying. In addition, the fused pyrrolocarbazoles may be useful for inhibition of c-met, c-kit, and mutated Flt-3 containing internal tandem duplications in the juxtamembrane domain.
Because of these varied activities, the disclosed compounds find utility in a variety of settings, including research and therapeutic environments.
In another aspect of the present invention there is provided pharmaceutical compositions comprising a fused pyrrolocarbazole of the present invention wherein the compositions comprise a pharmaceutically acceptable excipient or carrier and a therapeutically effective amount of at least one of the compounds of the present invention, or a pharmaceutically acceptable salt or ester form thereof.
In another aspect of the present invention there is provided methods of treating or preventing diseases or disorders comprising administering a therapeutic or preventative effective amount of at least one of the compounds of the present invention to a subject in need thereof.
These and other aspects, features and advantages of the fused pyrrolocarbazoles will be disclosed in the following detailed description of the patent disclosure.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS One embodiment of the present invention are the fused pyrrolocarbazoles represented by Formula I: Formula I wherein
R
1 and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and
R
3 is -CH 2 0H; -CH 2 0R 7
-(CH
2 )nSR 5
-(CH
2 )nS(O)yR 5
-CH
2
SR
5 or alkyl of 1-8 carbons substituted with -OH, -OR 5
-OR
8
-CH
2 0R 7 -S(O)yR 6 or -SR 6 and wherein
R
5 is alkyl of 1-4 carbons or aryl;
R
6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons;
R
7 is H or alkyl of 1-4 carbons;
R
8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2; with the proviso that when R 1 is (CH 2 3 0H and R 2 is H, then R 3 cannot be
-CH
2 0H, -CH 2 0CH 2
CH
3 or -CH 2
SCH
2
CH
3 In certain preferred embodiments, the compounds of Formula I are those of Formula II: WO 02/17914 WO 0217914PCT/US01/26266 R R Formula 11 wherein R2, and W? are as defined for Formula I above.
In certain referred embodiments, R' is an alkyl of 1-4 carbons (inclusive), substituted with -OH or -ORW where W? is an alkyl of 1-4 carbons (inclusive), aryl, preferably phenyl or naphithyl, or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; RW is H; and W? is -CH 2 0H-; -CH 2
OR
7 -(CHA)SR; -(CH 2
),,S(O)YR
5
-CH
2
SR
5 or alkyl of 1 -8 carbons (inclusive), preferably an alkcyl of 1-4 carbons (inclusive), substituted with OH, -OR 5
-CH
2
OR
7
-S(O)YR
6 or SR 6 wherein RW, RW, R! and R! are as defined for Fornula I above.
In certain other preferred embodiments, R 1 is -CH 2
CH
2
CH
2 OH or
CH
2
CH
2
CH
2
OCOCH
2
N(CH
3 2 W? is H and W? is -CH 2
OR
7 wherein R7 is alkyl of 1-4 carbons (inclusive).
In certain even fuirther preferred embodiments the fused pyrrolocarbazoles of Formula I and Formula 11 are those represented in Table I: Table I Cmpd R'LRZR 1 CH 2
CH
2
CH
2 OH H CH 2
OCH
2
CH
3 2 CH 2
CH
2
CH
2 OH H CH 2
OCH
3 3 CI- 2
CH
2
CH
2 OH H CH 2
OCH(CH
3 2 4 CH 2
CH
2
CH
2 OH H CH 2
OCH(CH
3
)CH
2
CH
3
CH
2
CH
2
CH
2 OH H (S)-CII 2
OCH(CH
3
)CH
2
CT
3 WO 02/17914 WO 0217914PCT/USO1/26266 Cmpd R yR 6 CH 2
CH
2
CH
2 OH H
CH
9
)OCH(CH
3 )CI1 2 CHl 3 7 CH 2
CHOHCH
3 H- CH 2
OCHI
2
CH
3 8 CH 2
GH
2
CH
2 OH- H CH 2
OCH
2
CH
2
CH
3 9CH 2
CH
2
CH
2 OH H CH 2
OCH
2
CHCHC
3
GH
2
CH
2
CH
2 OH H CH(CH 3
)OCH
2
CH
3 I1I CH 2
CH
2
CH
2 OH H (chiral) CH(CH 3
)OCH
2
CH
3 12 CH 2
CHCH
2 OH H (chiral) CH(CH 3
)OCH
2 CHf 3 13 CH 2
CH
2
GH
2 OH H CH(CH 3
)OCH
3 14 H CH 2
CHOHCH
3
CH
2
OCH
2
CH
3
CH
2
CH
2
CH
2 OH H CH(CH 3
)OCH
2
GH
2
CH
2
GH
3 16 CH 2
CH
2
CH
2 OH H CH(GH 3
)OCH(CH
3 2 17 CH 2
CH
2
CH
2 OH H CH 2
OC(CH
3 3 18 CH 2
CH
2
CH
2
OCOCH
2
NH
2 H CH 2
OGH(CH
3 2 19 CH 2
CH
2
GH
2
OCOCH(NH
2
)CH
2 H CH 2
OCH(CH
3 2
CH
2
CH
2
CH
2
NH-
2
CH
2
GH
2
CH
2 OCOC14 2
CH
2
NH
2 H CH 2
OGH(CH
3 2 21 CH 2
CH
2
CH
2
OCOCHCH
2 H CtLOCH(CH 3 2
CH
2
N(CH
3 2 22 CH 2
CH
2
CH
2
OCOCH
2
N(CH
3 2 H CH 2
OCH(CH
3 2 23 CH 2
CH
2
CH
2
OCOCH
2
CH
2
CH
2 H CH 2
OCH(CH
3 2
CH
2
CH
2
NH
2 24 CH 2
CH
2 OH H CH 2
SCH
2
CH
3
CH
2
CH
2
CH
2 OH H CH 2
SCH
2
CH
3 26 CH 2
CH
2
CH
2 OH H CH 2
S(O)CH(CH
3 2 27 CH 2
CH
2
CH
2 OH H CH 2
SCH-(CH
3 2 28 CH 2
CH
2 OH H CH 2 0H 29 CH 2
CH
2
CH
2 OH H CH 2 0H H H CH 2 0H 31 H H CH 2
OCH
2
CH
3 32 H H CH 2
OCH(CH
3 2 33 CH4 2
CH
2
CH
2 OH H CH(OHI)CH 3 34 CH 2
CH
2
CH
2 OH H CH(OH-)CH 2
CH
3 WO 02/17914 WO 0217914PCT/US01/26266 Cmpd R ZR HH
CHI(OH)CH
3 36 H H CH(OCH 3
)CH
3 37 CH 2 CHl 2
CH-
2 OCOCF, H CH 2
SCH
2
CH
2
CH
3 38 CH 2
CH
2
CH
2 OH H CH 2 S(2-pyridyl) 39 CH 2
CH
2
CH
2 OH H CH 2 S(2-pyrhmidyl)
CH
2
CH
2
CH
2 OH CH 2 0H CH 2
OCH(CH
3 2 Preferred fused pyrrolocarbazoles of Formula II are represented structurally in Table II: Table 11 WO 02/17914 WO 0217914PCT/US01/26266
(S)H
0JN
H
H
0 N 0
I
N
OH
H
N
0 0
N
,-OH
WO 02/17914 WO 0217914PCT/US01/26266
K
0
H
100
OH
chiral H
N
O 0 11-
N
,-OH
chiral
H
0 N 0 12
N
H
N
0 13
N
,-OH
N
0 0 14-
N
H OH WO 02/17914 PCT/USO1/26266 WO 02/17914 WO 0217914PCT/US01/26266 -11-
H
0N 0 21
N
NMe 2
H
0N 0 22 N K 0 L.OIK/NMe,
H
N
o 0 23N 0 0l~l NH 2
H
S 0 24N
H
K N 251N/K
OH
H
N~ 0 26 a
OH
WO 02/17914 PCT/USO1/26266 -12- WO 02/17914 WO 0217914PCT/USO1/26266
H
N
OH 0 34
N
,\OH
H
N
OH 0
N
H
0 N 0 36
N
H
WO 02/17914 PCT/US01/26266
H
3 8
S.
4 o
OH
H
N N S aN 0
OHOH
H
Particularly preferred compounds of Table II include compounds 1, 3, 4, 5, 6, 7 and 22 with compounds 3 and 22 being most preferred.
The compounds represented by Formula I and II and depicted in Tables I and II may also be referred to herein as "the compounds," "the compound(s) of the present invention," "fused pyrrolocarbazole(s)," "fused pyrrolocarbazole(s) of the present invention" and the like.
WO 02/17914 PCT/USO1/26266 Certain compounds of U.S. Patent 5,705,511 are depicted in Table lia.
Table ia, WO 02/17914 PCT/US01/26266 -16- As used herein with reference to the definitions of R 1 and R 2 the term "amino acid" denotes a molecule containing both an amino acid group and a carboxyl group. It includes an "a-amino acid" which has its usual meaning as a carboxylic acid which bears an amino functionality on the carbon adjacent to the carboxyl group. a-Amino acids can be naturally occurring or non-naturally occurring. Amino acids also include "dipeptides" which are defined herein as two amino acids which are joined in a peptide linkage Thus constituents of dipeptides are not limited to a-amino acids, and can be any molecule containing both an amino group and a carboxyl group. Preferred are a-amino acids, dipeptides such as lysyl-P-alanine, and aminoalkanoic acids of 2-8 carbons, 3dimethylaminobutyric acid.
Pharmaceutically acceptable salts of the fused pyrrolocarbazoles of the present invention also fall within the scope of the compounds as disclosed herein. The term "pharmaceutically acceptable salts" as used herein means an inorganic acid addition salt such as hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate, tartrate, and citrate. Examples of pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt.
Examples of pharmaceutically acceptable ammonium salts are ammonium salt and tetramethylammonium salt. Examples of pharmaceutically acceptable organic amine 2 0 addition salts are salts with morpholine and piperidine. Examples of pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.
Compounds provided herein can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients or carriers. As noted above, such compositions may be prepared for use in parenteral administration, particularly in the form of liquid solutions or suspensions; or oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, via, for example, trans-dermal patches.
Accordingly, another aspect of the present invention are pharmaceutical compositions comprising a compound of the present invention optionally in admixture with one or more pharmaceutically acceptable excipients or carriers. Preferably, the WO 02/17914 PCT/US01/26266 -17pharmaceutical compositions comprise a compound of Formula II. More preferably, the pharmaceutical compositions comprise a compound of Table I or Table II.
In certain preferred pharmaceutical compositions, the composition is for inhibiting one or more of trk kinase activity, VEGFR kinase activity, PKC or PDGFR activity wherein the composition comprises a compound of Formula I, Formula II, Table I or Table II and optionally one or more pharmaceutically acceptable carrier(s). In other preferred pharmaceutical compositions the composition is for enhancing tropic factor or spinal chord ChAT activity wherein the composition comprises a compound of Formula I, Formula II, Table I or Table II and a pharmaceutically acceptable carrier.
In other preferred pharmaceutical compositions, the composition is for treating or preventing angiogenesis and angiogenic disorders such as cancer of solid tumors, endometriosis, retinopathy, diabetic retinopathy, psoriasis, hemangioblastoma, ocular disorders or macular degeneration. In other preferred pharmaceutical compositions, the composition is for treating or preventing neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis. In other preferred pharmaceutical compositions, the composition is for treating or preventing neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, chemotherapy induced peripheral neuropathy, AIDS related peripheral neuropathy, or injuries of the brain or spinal chord.
In other preferred pharmaceutical compositions, the composition is for treating or preventing prostate disorders such as prostate cancer or benign prostate hyperplasia. In still other preferred pharmaceutical compositions, the composition is used for treating or preventing multiple myeloma and leukemias including, but not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia.
The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980). Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils WO 02/17914 PCT/US01/26266 -18and vegetable origin, hydrogenated naphthalenes and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, a salicylate for rectal administration, or citric acid for vaginal administration. Formulations for trans-dermal patches are preferably lipophilic emulsions.
The compounds of the present invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients, e.g., other growth factors which could facilitate neuronal survival or axonal regeneration in diseases or disorders or other angiogenesis or antitumor agents.
The concentrations of the compounds described herein in a therapeutic or pharmaceutical composition will vary depending upon a number of factors, including the 2 0 dosage of the drug to be administered, the chemical characteristics hydrophobicity) of the compounds employed, and the route of administration. In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v compound for parenteral administration.
Typical dose ranges are from about 1 tg/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.01 mg/kg to 100 mg/kg of body weight per day.
The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.
In other embodiments, the present invention provides a method for inhibiting trk kinase activity comprising providing a compound of the present invention in an amount WO 02/17914 PCT/US01/26266 -19sufficient to result in effective inhibition. In a preferred embodiment, the compound of the present invention is provided to treat inflammation, for example, neurological inflammation and chronic arthritis inflammation. In another preferred embodiment, the trk kinase receptor is trk A.
In other embodiments, the present invention provides a method for treating or preventing prostate disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention. In a preferred embodiment, the prostate disorder is prostate cancer or benign prostate hyperplasia.
In other embodiments, the present invention provides a method for treating or preventing angiogenic disorders where VEGFR kinase activity contributes to pathological conditions, the method comprising providing a compound of the present invention in an amount sufficient to result in the vascular endothelial growth factor receptor being contacted with an effective inhibitory amount of the compound. In another embodiment, the present invention provides a method for treating or preventing angiogenic disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention.
In a preferred embodiment, the angiogenic disorder is cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma.
In other embodiments, the present invention provides a method for treating or preventing disorders where PDGFR activity contributes to pathological conditions, the method comprising providing a compound of the present invention in an amount sufficient to result in the platelet derived growth factor receptor being contacted with an effective inhibitory amount of the compound. In another embodiment, the present invention provides a method for treating or preventing pathological disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention. In preferred embodiments, the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis.
WO 02/17914 PCT/US01/26266 In other embodiments, the present invention provides a method for treating disorders characterized by the aberrant activity of trophic factor responsive cells, the method comprising providing a compound of Formula I, Formula II, Table I or Table II in an amount sufficient to result in the trophic factor cell receptor being contacted with an effective activity inducing amount of the compound. In preferred embodiments, the activity of the trophic factor responsive cells is ChAT activity. In another embodiment, the present invention provides a method for treating or preventing neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral neuropathy or injuries of the brain or spinal chord which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of Formula I, Formula II, Table I and Table II.
As used herein, the term "effect" when used to modify the terms "function" and "survival" means a positive or negative alteration or change. An effect which is positive can be referred to herein as an "enhancement" or "enhancing" and an effect which is negative can be referred to herein as "inhibition" or "inhibiting." As used herein, the terms "enhance" or "enhancing" when used to modify the terms "function" or "survival" means that the presence of a fused pyrrolocarbazole has a 2 0 positive effect on the function and/or survival of a trophic factor responsive cell compared with a cell in the absence of the fused pyrrolocarbazole. For example, and not by way of limitation, with respect to the survival of, a cholinergic neuron, the fused pyrrolocarbazole would evidence enhancement of survival of a cholinergic neuronal population at risk of dying (due to, injury, a disease condition, a degenerative condition or natural progression) when compared to a cholinergic neuronal population not presented with such fused pyrrolocarbazole, if the treated population has a comparatively greater period of functionality than the non-treated population. As a further example, and again not by way of limitation, with respect to the function of, e.g., a sensory neuron, the fused pyrrolocarbazole would evidence enhancement of the function neurite extension) of a sensory neuronal population when compared to a sensory neuronal population not presented with such fused pyrrolocarbazole, if the WO 02/17914 PCT/US01/26266 -21neurite extension of the treated population is comparatively greater than the neurite extension of the non-treated population.
As used herein, "inhibit" and "inhibition" mean that a specified response of a designated material enzymatic activity) is comparatively decreased in the presence of a fused pyrrolocarbazole of the present invention.
As used herein the term "neuron," "cell of neuronal lineage" and "neuronal cell" includes, but is not limited to, a heterogeneous population of neuronal types having singular or multiple transmitters and/or singular or multiple functions; preferably, these are cholinergic and sensory neurons. As used herein, the phrase "cholinergic neuron" means neurons of the Central Nervous System (CNS) and Peripheral Nervous System (PNS) whose neurotransmitter is acetylcholine; exemplary are basal forebrain and spinal cord neurons. As used herein, the phrase "sensory neuron" includes neurons responsive to environmental cues temperature, movement) from, skin, muscle and joints; exemplary is a neuron from the DRG.
As used herein a "trophic factor" is a molecule that directly or indirectly affects the survival or function of a trophic factor responsive cell. Exemplary trophic factors include Ciliary Neurotrophic Factor (CNTF), basic Fibroblast Growth Factor (bFGF), insulin and insulin-like growth factors IGF-I, IGF-II, IGF-III), interferons, interleukins, cytokines, and the neurotrophins, including Nerve Growth Factor (NGF), Neurotrophin-3 Neurotrophin-4/5 (NT-4/5) and Brain Derived Neurotrophic Factor (BDNF).
A "trophic factor-responsive cell," as defined herein, is a cell which includes a receptor to which atrophic factor can specifically bind; examples include neurons cholinergic and sensory neurons) and non-neuronal cells monocytes and neoplastic cells).
As used herein, "trophic factor activity" and "trophic factor induced activity" are defined as any response which directly or indirectly results from the binding of a trophic factor NGF) to a cell comprising a trophic factor receptor neuron comprising of a trk). In the case of, NGF binding with trk, an exemplary response would include autophosphorylation of trk tyrosine residues leading to increased ChAT activity which results in enhanced neuron survival, and/or function.
WO 02/17914 PCT/US01/26266 -22- As used in the phrases "trophic factor activity" and "trophic factor-induced activity," the term "trophic factor" includes both endogenous and exogenous trophic factors, where "endogenous" refers to a trophic factor normally present and "exogenous" refers to a trophic factor added to a system. As defined, "trophic factor induced activity" includes activity induced by endogenous trophic factors; exogenous trophic factors; and a combination of endogenous and exogenous trophic factors.
As used herein, the term "trk" refers to the family of high affinity neurotrophin receptors presently comprising trk A, trk B and trk C, and other membrane associated proteins to which a neurotrophin can bind.
As used herein the phrase "hyperproliferative state" in reference to the term "cells" means cells whose unregulated and/or abnormal growth can lead to the development of an unwanted condition, for example, a cancerous condition or a psoriatic condition.
As used herein, "cancer" and "cancerous" refer to any malignant proliferation of cells in a mammal. Examples include prostate, benign prostate hyperplasia, ovarian, breast and other recognized cancers. As used herein the term "psoriasis" and "psoriatic condition" refer to disorders involving keratinocyte hyperproliferation, inflammatory cell infiltration and cytokine alteration.
As used herein, the phrase "at risk of dying" in conjunction with a biological material, a cell such as a neuron, means a state or condition which negatively impacts the biological material such that the material has an increased likelihood of dying due to such state or condition. For example, compounds disclosed herein can "rescue" or enhance the survival of motoneurons which are naturally at risk of dying in an in ovo model of programmed cell death. Similarly, for example, a neuron may be at risk of dying due to the natural aging process which occasions the death of a neuron, or due to an injury, such as a trauma to the head, which may be such that neurons and/or glia, for example, impacted by such trauma may be at risk of dying. Further, for example, a neuron may be at risk of dying due to a disease state or condition, as in the case of neurons at risk of dying as occasioned by the disease ALS. Thus, by enhancing the survival of a cell at risk of dying by use of a compound of the claimed invention is meant that such compound decreases or prevents the risk of the death of the cell.
WO 02/17914 PCT/US01/26266 -23- As used herein the term "contacting" means directly or indirectly causing placement together of moieties, such that the moieties directly or indirectly come into physical association with each other, whereby a desired outcome is achieved. Thus, as used herein, one can "contact" a target cell with a compound as disclosed herein even though the compound and cell do not necessarily physically join together (as, for example, is the case where a ligand and a receptor physically join together), as long as the desired outcome is achieved enhancement of the survival of the cell).
Contacting thus includes acts such as placing moieties together in a container adding a compound as disclosed herein to a container comprising cells for in vitro studies) as well as administration of the compound to a target entity injecting a compound as disclosed herein into a laboratory animal for in vivo testing, or into a human for therapy or treatment purposes).
As used herein, "prodrug" is intended to include any covalently bonded carriers which release the active parent drug as a compound of the present invention in vivo when such prodrug is administered to a mammalian subject. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention contemplates prodrugs of the compounds of the present invention, compositions containing the same, and methods of treating diseases and disorders with such prodrugs. Prodrugs of a compound of the present invention, for example Formula I, may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Accordingly, prodrugs include, for example, compounds of the present invention wherein a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or carboxylic acid, respectively.
Examples include, but are not limited to, the residue of an amino acid after the hydroxyl group of the carboxy] group is removed acetate, formate and benzoate derivatives of alcohol and amine functional groups; and alkyl, carbocyclic, aryl, and alkylaryl esters 3 0 such as methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.
23a Comprises/comprising and grammatical variations thereof when used in C this specification are to be taken to specify the presence of stated features, Sintegers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
00 WO 02/17914 PCT/US01/26266 -24- The fused pyrrolocarbazoles of the present invention have important functional pharmacological activities which find utility in a variety of settings, including both research and therapeutic arenas. For ease of presentation, and in order not to limit the range of utilities for which these compounds can be characterized, we generally describe the activities of the fused pyrrolocarbazoles as follows: 6. Inhibition of enzymatic activity 6. Effect on the function and/or survival of trophic factor responsive cells 6. Inhibition of inflammation-associated responses 6. Inhibition of cell growth associated with hyperproliferative states 6. Inhibition of developmentally programmed motoneuron death Inhibition of enzymatic activity can be determined using, for example, VEGFR inhibition VEGFR2 inhibition), MLK inhibition MLK1, MLK2 or MLK3 inhibition), PDGFR kinase inhibition, NGF-stimulated trk phosphorylation, PKC inhibition, or trk tyrosine kinase inhibition assays. Effect on the function and/or survival of trophic factor responsive cells, cells of a neuronal lineage, can be established using any of the following assays: cultured spinal cord choline acetyltransferase ("ChAT") assay; cultured dorsal root ganglion neurite extension assay; (3) cultured basal forebrain neuron ChAT activity assay. Inhibition of inflammation-associated response can be established using an indoleamine 2,3dioxygenase mRNA assay. Inhibition of cell growth associated with hyperproliferative states can be determined by measuring the growth of cell lines of interest, such as an AT2 line in the case of prostate cancer. Inhibition of developmentally programmed motoneuron death can be assessed in ovo using embryonic chick somatic motoneurons, which cells undergo naturally occurring death between WO 02/17914 PCT/US01/26266 embryonic days 6 and 10, and analyzing inhibition of such naturally occurring cell death as mediated by the compounds disclosed herein.
The inhibition of enzymatic activity by the fused pyrrolocarbazole compounds of the present invention can be determined using, for example, the following assays: VEGFR Inhibition Assay MLK Inhibition Assay PKC Activity Inhibition Assay trkA Tyrosine Kinase Activity Inhibition Assay Inhibition of NGF-stimulated trk phosphorylation in a whole cell preparation Platelet Derived Growth Factor Receptor (PDGFR) inhibition assay Particularly, inhibition of the Vascular Endothelial Growth Factor Receptor (VEGFR) implies utility in, for example, diseases where angiogenesis plays important roles, such as cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, as well as other ocular diseases and cancers. Inhibition of MLK implies utility in, for example, neurological diseases. Inhibition of trk implies utility in, for example, diseases of the prostate such as prostate cancer and benign prostate hyperplasia, and treatment of inflammatory pain. Inhibition of the Platelet Derived Growth Factor Receptor (PDGFR) implies utility in, for example, various forms of neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, diseases with cardiovascular end points, such as atherosclerosis, restenosis, postangioplasty restenosis, and the like.
Fused pyrrolocarbazoles have also been shown to have positive effects on the function and survival of trophic factor responsive cells by promoting the survival of neurons. With respect to the survival of a cholinergic neuron, for example, the compound may preserve the survival of a cholinergic neuronal population at risk of WO 02/17914 PCT/US01/26266 -26dying (due to, injury, a disease condition, a degenerative condition or natural progression) when compared to a cholinergic neuronal population not presented with such compound, if the treated population has a comparatively greater period of functionality than the non-treated population.
A variety of neurological disorders are characterized by neuronal cells which are dying, injured, functionally compromised, undergoing axonal degeneration, at risk of dying, etc. These disorders include, but are not limited to, neurological diseases and disorders, Alzheimer's disease; motor neuron disorders amyotrophic lateral sclerosis); Parkinson's disease; cerebrovascular disorders stroke, ischaemia); Huntington's disease; AIDS dementia; epilepsy; multiple sclerosis; peripheral neuropathies those affecting DRG neurons in chemotherapy-associated peripheral neuropathy) including diabetic neuropathy and AIDS related peripheral neuropathy; disorders induced by excitatory amino acids; and disorders associated with concussive or penetrating injuries of the brain or spinal cord.
The compounds are not only useful for enhancing trophic factor-induced activities of trophic responsive cells, cholinergic neurons, but also may function as survival promoting agents for other neuronal cell types, dopaminergic or glutamatergic. Growth factor may regulate survival of neurons by signaling cascades downstream of the small GTP binding proteins ras, rac, and cdc42 (Denhardt, D.T., Biochem. 1996, 318, 729). Specifically, activation of ras leads to phosphorylation and activation of extracellular receptor-activated kinase (ERK), which has been linked to biological growth and differentiation processes.
Stimulation of rac/cdc42 leads to an increase in activation of JNK and p 3 8, responses that are associated with stress, apoptosis, and inflammation. Although growth factor responses are primarily via the ERK pathway, affecting these latter processes may lead to alternative mechanisms of neuronal survival which may mimic growth factor enhancing survival properties (Xia et al., Science, 1995, 270, 1326). The compounds of the present invention may also function as survival promoting agents for neuronal and non-neuronal cells by mechanisms related to, but also distinct from, growth factor mediated survival, for example, inhibition of the JNK and p38 MAPK pathways which may lead to survival by inhibition of apoptotic cell death processes. The present WO 02/17914 PCT/US01/26266 -27compounds are also useful in the treatment of disorders associated with decreased ChAT activity or the death, injury to spinal cord motoneurons, and also have utility in, for example, diseases associated with apoptotic cell death of the central and peripheral nervous system, immune system and in inflammatory diseases. ChAT catalyzes the synthesis of the neurotransmitter acetylcholine, and it is considered an enzymatic marker for a functional cholinergic neuron. A functional neuron is also capable of survival.
Neuron survival is assayed by quantitation of the specific uptake and enzymatic conversion of a dye calcein AM) by living neurons. The compounds described herein may also find utility in the treatment of disease states involving malignant cell proliferation, such as many cancers.
Because of their varied utilities, the properties of isomeric fused pyrrolocarbazoles and isoindolones may be exploited in other settings, such as research.
For example, the compounds can be used in the development of in vitro models of neuronal cell survival, function, identification, or for the screening of other synthetic compounds which have activities similar to that of the of isomeric fused pyrrolocarbazole and isoindolone compounds. Thus, the compounds provided by this invention are useful as standard or reference compounds for use in tests or assays for detenmining the activity of an agent in a pharmaceutical research program.
The compounds can also be utilized to investigate, define and determine molecular targets associated with functional responses. For example, by radiolabelling an isomeric fused pyrrolocarbazole or isoindolone compound associated with a specific cellular function mitogenesis), the target entity to which the derivative binds can be identified, isolated, and purified for characterization. By way of further illustration, compounds may be used in the development of assays and models for further enhancement of the understanding of the roles that inhibition of serine/threonine or tyrosine protein kinase PKC, trk tyrosine kinase) play in the mechanistic aspects of the associated disorders and diseases. Thus, the compounds of the present invention are useful as diagnostic reagents in diagnostic assays, such as the assays described herein.
The results obtained in the VEGFR and MLK assays are set forth below. Other assays are described in more detail as well. They are not intended, nor are they to be construed, as limiting the scope of the disclosure. Certain abbreviations used to delineate WO 02/17914 PCT/US01/26266 -28the results below are defined as follows: "pjg" denotes microgram, "mg" denotes milligram, denotes gram, "ptL" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "tM" denotes micromolar, "mM" denotes millimolar, denotes molar and "nm" denotes nanometer.
Synthesis The present invention also provides a method for preparing the fused pyrrolocarbazoles of the present invention. The compounds of the present invention may be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by the methods described in the Schemes below, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions being readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
It will be appreciated that the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare such 2 0 optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from active starting materials or by deliberate chiral synthesis of target centers.
As will be readily understood, functional groups present on the compounds of the present invention may contain protecting groups. For example, the amino acid side chain substituents of the compounds can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups. Protecting groups are known per se as WO 02/17914 PCT/US01/26266 -29chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Preferred protecting groups include the benzyloxycarbonyl (Cbz; Z) group and the tert-butyloxycarbonyl (Boc) group. Other preferred protecting groups according to the invention may be found in Greene, T.W. and Wuts, "Protective Groups in Organic Synthesis" 2d. Ed., Wiley Sons, 1991.
Scheme 1
H
0
DBU
ethyl acrylate
SCH
3
CN
H
1N
II
pTsOH
DMB-OH
NMP
Benzene N 0 c- 0 'N 1. LiBH 4 THF (IV) 2. NBS
THF
H
O
HO
DIBAL-H
CH2CI2
HO
TEA Example 29 TFAACH VIII CH2CI2 cc HaOAc PdC12(PPh3)2 Br, 2-methoxyethanol 1550C TFA VI Thioanisole VII WO 02/17914 WO 0217914PCT/USOI/26266 Scheme 2
H
0 H
HO
Example 29 H H H
H
0 0 No L QAc OH Example 28 Scheme 3
H
N
RI= H, (Cl-2) 3 0H
H
OH0 R
KN
Xl R 2 (CH2) 3 0H XII R 2
=H
Example 30 R2 H, R7 H Example 35 R2 R7=Me Example 34 R2 =(CH 2 3 0H, R7 Et Example 33 R2 (CH 2 3 0H, R7 Me WO 02/17914 WO 0217914PCT/US01/26266 Scheme 4
H
OR
5
N
R
N
H FR50 R OH 0 R
H
R
2 R S
R
General Structure IX R R2=H, (Cft)20H, (CFt)30H K N R7 Me, Et WO 02/17914 WO 0217914PCT/US01/26266 -32- Scheme NaH
OMF
Example 31 Super hydride
THF
HO
Example 7 Scheme 6
CSCO
3 0
CHC!
2 MeOH H o-
ITFA
CHCI
2 Example 14 WO 02/17914 WO 0217914PCT/US01/26266 -33- Scheme 7
TBS
HN o TBSCI,Et~N
O
TBS tBuMe 2 Si- HO
TBSO
Example 3 XVIII Triton B/pyridine, Sparaformaldehyde H TBS N 0
N
0 '0 iPrOH, TMSCI I 0
TESO
Example WO 02/17914 PCT/US01/26266 -34- Scheme 8 H H N 'N Example 3 R Example 18 R CH 2
NH
2 Example 19 R CH(NH 2 )(CH2)4NH2 Example 20 R (CH 2 )2NH 2 Example 21 R (CH 2 3 N(CH3) 2 Example 22 R CH 2 N(CH3) 2 Example 23 R (CH 2 5
NH
2 Description of Synthesis Compounds A and B were prepared by alkylation's of indole I with 2-bromoethyl benzyl ether or with 3-bromopropyl benzyl ether using NaH in DMF, followed by debenzylation (Pd(OH) 2
/H
2 as described in US Patent 5 705 511. Reference compound C was prepared by coupling B with Boc-leucine followed by deprotection of the BOC group using standard procedures know to those skilled in the art of organic synthesis. Compound B may also be prepared by reduction of ester IV with reducing agents such as LiBH 4 followed by removal of the benzhydrol protecting group. The routes to prepare the benzyl ethers and thiol ethers are outlined in the schemes. Two methods are used to prepare the 3-hydroxymethyl intermediates 28-30, 33-35. Scheme 1 (Method A) delineates a carbonylation route while scheme 2 (method B) utilizes a formylation method. In scheme 1 Michael reaction of I with ethyl acrylate and a base such as DBU produces II, followed by lactam nitrogen protection with WO 02/17914 PCT/US01/26266 dimethoxybenzhydrol to III. Reduction of the ethyl ester using reducing agents such as lithium borohydride, followed by bromination with N-bromo succinimide provided intermediate V in good overall yield. Palladium catalyzed carbonylation of V in methoxyethanol gave the methoxyethoxy ester VI. After deprotection to VII, the ester could be reduced with reducing agents, for example diisobutylaluminum hydride (DIBAL-H) to give the diol 29. The formylation route to the hydroxymethyl compounds (method B, scheme 2) uses for example, HMTA in TFA or ac,a-dichloromethyl methyl ether and a Lewis acid. The aldehydes may be reduced to hydroxymethyl compounds using reducing agents such as sodium borohydride or diisobutylaluminum hydride. The methyl ether or thio ether examples may be prepared using a general procedure outlined in scheme 4. In one approach, for example, the diol 29 may be converted to a tritrifluoroacetate intermediate with trifluoroacetic anhydride and a base such as triethylamine, followed by treating this intermediate with an appropriate alkyl alcohol or alkyl thiol to give the benzyl ether (1-25, 27, 31, 32, 36-40) directly. In certain cases the trifluoroacetate ester of the primary alcohol may be isolated. In these examples the alcohol may be isolated by treatment of the trifluoroacetate with a base such as lithium hydroxide. In another approach, the ethers and thio ethers may be prepared by reacting a diol, for example 28 or 29, with an alcohol and an acid catalyst, such as p-toluene sulfonic acid or camphorsulfonic acid in a solvent, for example, methylene chloride, toluene or 1,2-dichloroethane.
Alcohols 33-35 were used to prepare ether examples 10-13, 15, 16 and 36.
Examples 33-35 were prepared from ketones XI and XII as outlined in scheme 3. The ethers and thio ethers were prepared using the procedures described previously and outlined in scheme 4.
Example 7 was prepared as shown in scheme 5. Example 31 was alkylated with mesyl glycidol to give compound XIII. Reduction with triethylborohydride in THF produced example secondary alcohol 7. Example 14 was prepared (scheme 6) by treatment of compound XIV with cesium carbonate and acetaldehyde in methylene chloride/methanol. Example 40 was prepared as shown in scheme 7. The Di-TBS protected XVIII, was alkylated with paraformaldehyde using triton B/pyridine, followed by deprotection using TMSC1 to give example 40. The amino acid esters, example 18-23 WO 02/17914 PCT/US01/26266 -36were prepared from example 3 and the corresponding carboxylic acid using standard coupling reaction known to those skilled in the art of organic synthesis.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments. These examples are given for illustration of the invention and are not intended to be limiting thereof.
Examples Certain abbreviations used herein are defined as follows: for degrees Celsius, for doublet, "dd" for doublet of doublets, for triplet, for multiplet, "eq" for equivalents, for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, for hydrogen or hydrogens, "hr" for hour or hours, for multiplet, for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "nmr" or "NMR" for nuclear magnetic resonance spectroscopy.
Preparation of compound II: To a suspension of I (8.0 g, 0.258 mols) in acetonitrile (300 mL) at room temperature under nitrogen was added ethyl acrylate (4.19 mL, 0.387 mols) followed by 1,8diazabicyclo[5.4.0]undec-7-ene (DBU) (1.93mL, 0.013 mols). After addition of DBU, the reaction changed colors from orange to green. The reaction mixture was heated to reflux overnight. The mixture remained heterogeneous throughout the course of the reaction and became dark in color. A small aliquot was removed after 18 h and the solid was collected by filtration. 'H NMR of the sample showed no starting material remaining. The reaction mixture was cooled to room temperature and the solid was collected by filtration. The solid was washed several times with cold acetonitrile and dried in vacuo at 55 °C to yield a light orange solid (5.4 g, 78 yield). 'H NMR (DMSO-d6, 300 MHz): 8 9.72 3H, J 6. 2.87 2H), 3.89 2H, J 4.49 2H), 4.88 2H), 4.92 2H), 7.29-7.48 3H), 7.50-7.73 3H), 7.96 1H, J 7.33), 8.56 1H), 9.47 1H, J 7.33).
WO 02/17914 PCT/US01/26266 -37- Preparation of compound III: To a suspension of II (5.62 g, 0.0137 mols) in benzene (300 mL) and Nmethylpyrrolidine (NMP) (60 mL) at room temperature under nitrogen was added ptoluenesulfonic acid monohydrate (2.48 g, 0.013 mols) and 4,4'-dimethoxybenzhydrol (3.19 g, 0.013 mols). The contents of the flask were heated to reflux for 8 h. After min., the initially heterogeneous reaction mixture became homogeneous. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (300 mL) and washed with a saturated bicarbonate solution, water, and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo to an orange solid (8.31 g, 95 yield). 'HNMR (CDC 3 300 MHz): 8 1.18 3H, J 2.84 2H), 3.80 (6H, s), 4.12 2H, J 4.38 2H), 4.72 (2H, 4.94 2H), 6.90 4H, J 6.955 1H), 7.26 4H, J 7.34-7.49 5H), 7.61 1H, J 7.69 1H, J= 9.65 1H, J 7.8).
Preparation of compound IV: To a stirred solution of III (7.8 g, 0.0122 mols) in THF (480 mL) and methanol (93 mL) was added lithium borohydride (18.9 mL of a 2.0 M soln, 0.0379 mols) dropwise. The reaction mixture was initially homogeneous, however, as the reaction proceeded, the mixture became heterogeneous. When all of the starting material had been consumed, the reaction mixture was cooled in an ice bath and carefully quenched with 2N HC1 mL). The reaction mixture became homogeneous and light orange in color. Water (750 mL) was added to the mixture and a milky white precipitate formed. The precipitate was collected by filtration and dried in vacuo to give a fluffy white solid (7.2 g, 99 yield).
'H NMR (DMSO-d 6 300 MHz): 8 1.93 2H), 3.66 2H), 3.71 6H), 4.55 (s, 2H), 4.73 (in, 2H), 4.79 2H), 6.70 1H), 6.93 4H, J 8.44), 7.22 4H, J 7.26 1H), 7.34-7.46 2H), 7.49 1H), 7.65 (d,lH, J 7.01), 7.70 1H, J 8.26), 7.86 1H, J 7.82), 9.49 1H, J 7.49).
Preparation of compound V: To a suspension of IV (2.02 g, 0.0034 mols) in THF (131 mL) at room temperature under nitrogen was added N-bromosuccinimide (0.63 g, 0.0036 mols) in one portion. The WO 02/17914 PCT/US01/26266 -38reaction mixture stirred at room temperature overnight. The reaction solvent was removed in vacuo leaving a pale yellow solid. The solid was triturated with cold methanol and collected by filtration. The solid was dried in vacuo to give a pale yellow solid (1.98, 87 yield). 'H NMR (DMSO-d 6 300 MHz): 8 1.91 2H), 3.44 2H), 3.72 6H), 4.53 2H), 474 2H), 4.87 2H), 6.71 1H), 6.93 4H, J= 8.14), 7.25 4H, J 7.37 2H), 7.59-7.69 3H), 8.08 1H), 9.50 1H, J= 7.01).
Preparation of compound VI: In a Schlenk tube was placed V (0.79 g, 0.0017 mols) in methoxyethanol (25 mL) followed by sodium acetate (0.57 g, 0.00702 mols) and dichlorobis(triphenylphosphine)palladium(II) (0.082 g, 0.000117 mols). The tube was evacuated and filled with carbon monoxide. The reaction mixture was heated in the sealed tube at 155 °C in an oil bath for 3 h. The reaction was cooled to room temperature and additional carbon monoxide was added. The mixture was reheated to 150 oC for another 3 h. Additional CO and PdC1 2 (PPh 3 2 were added and the mixture heated for 4 h. The reaction mixture was diluted with methylene chloride and flushed through a pad of celite. The filtrate was concentrated in vacuo to a residue, which was dissolved in ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo to a solid which was triturated with ethyl ether and collected by filtration to yield a light orange solid (0.7 g, 85 yield). 'H NMR (CDClI, 300 MHz): 8 2.14 2H), 3.44 3H), 3.67-3.78 4H), 3.81 6H), 4.44 2H), 4.51 2H), 4.81 4H), 6.91 4H, J 8.53), 6.98 1H), 7.28 4H, 7.34-7.7.61 4H), 8.21 1H, J 8.32), 8.42 1H), 9.67 1H, J 7.61).
Preparation of compound VII: To a solution of VI (0.96 g, 0.00138 mols) in CH 2 Cl 2 (30 mL) at 0 OC under nitrogen was added thioanisole (3.2 mL, 0.110 mols) followed by trifluoroacetic acid (TFA)(8.5 mL, 0.0276 mols). Upon addition of TFA, the reaction mixture turned red in color. The mixture stirred at 0 'C for 1 h and was warmed to room temperature overnight. The reaction solvent was removed in vacuo leaving a dark red oil. Ethyl ether was added to WO 02/17914 PCT/US01/26266 -39the oil and the reaction mixture turned yellow in color and a tan solid precipitated out of solution. The solid was collected by filtration (0.6 g, 92 yield). 1 H NMR (DMSO-d 6 300 MHz): 8 2.29 2H), 3.3 2H), 3.73 2H), 4.45 2H), 4.54 3H), 4.82 2H), 4.99 2H), 7.40 2H), 7.58 1H), 7.85 1H), 8.13 1H), 8.52 1H), 8.6 1H), 9.49 1H).
Example 29 (method To a stirred suspension of VII (4.4 g, 0.00935 mols) in CHC1 2 (220 mL) at 0 oC under nitrogen was added DIBAL-H slowly dropwise. The reaction gradually became homogeneous. The orange-colored reaction mixture stirred at 0 °C for 1 h then was warmed to room temperature and was stirred for 6 h. The mixture was cooled to 0 °C in an ice bath and water (50 mL) was added extremely slowly initially. Vigorous evolution of gas was observed. An aqueous solution of NaOH (IM, 300 mL) was added and the reaction mixture stirred at room temperature for 1 h. A precipitate formed and was collected by filtration to yield a tan solid (3.6 g, 96 'H NMR (DMSO-d 6 300 MHz): 6 1.92 2H), 3.46 2H), 4.50 2H), 4.65 2H), 4.71 2H), 4.88 2H), 7.32-7.39 2H), 7.47 1H, J 8.34), 7.65 2H), 7.89 1H), 8.53 1H), 9.46 1H, J 7.44).
Preparation of compound X: To a stirred solution of II (2.77g, 6.75 mmols) in methylene chloride/ toluene 30/10 mLs) was added tin chloride (15 eq.) and a,ac-dichloromethylmethyl ether (20 The mixture changed colors from orange to dark green. The reaction mixture was monitored by HPLC for disappearance of starting material. The mixture was cooled to 0 oC and quenched with aq. HC1. The material was transferred to a round-bottomed flask and concentrated in vacuo to a green-brown oil. Additional HC1 and ethyl acetate were added and the material was again concentrated in vacuo. A brownish-pink solid precipitated out of solution. The solid was triturated with hexanes and the solvent decanted. This procedure was repeated 5 times. The solid was collected by filtration and dried to yield a light pinkish-brown solid 2.65 g (90% yield). MS (ESI): m/e 439 'H NMR (DMSO-d6, 300 MHz): 6 1.00 3H), 2.94 2H), 3.93 2H), 4.50 2H), 4.97 WO 02/17914 PCT/US01/26266 7.37 2H), 7.65 1H), 7.96 1H), 8.03 1H), 8.52 1H), 8.67 1H), 9.48 1H), 10.49 1H).
Example 29 (method To a suspension of compound X (2.37 g, 0.005 mol) in THF mL) at 0 °C under nitrogen was added lithium borohydride (10 The light brown mixture stirred at room temperature for 3.5 h after which no starting material was observed by HPLC. The mixture was cooled to 0 °C and methanol was added very slowly until no evolution of gas was observed. The mixture became homogeneous and then a precipitate began to form. The mixture was cone. In vacuo to a pale yellow solid which was triturated with water and collected by filtration to yield product 2.0 g (96% yield).
Preparation of compound VIII: To a suspension of Compound 29 (1.13 mmol, 1 eq.) in methylene chloride (30 mL) at 0 °C under nitrogen was added trifluoroacetic anhydride (3 eq.) followed by triethylamine (3 The reaction mixture gradually became homogeneous and stirred at 0 oC for 1 h then warmed to room temperature overnight. The mixture was diluted with methylene chloride and washed with water and brine. The organic phase was dried over magnesium sulfate, filtered and cone. In vacuo to a solid. This material was carried on without purification.
General procedure for ether formation (General Structure IX): 2 0 VIII was dissolved in the appropriate alcohol (0.025 M) and heated to 80 oC in an oil bath. The reaction mixture was monitored for disappearance of starting material. The mixture was cooled to room temperature and the solvent removed in vacuo leaving a solid. The resulting solid was triturated with ether and collected by filtration. In some cases, the products were further purified using chromatographic techniques.
The following compounds were prepared according to the above general procedure: Example 1: R 5 Oet, 18% purified yield; MS 427 H NMR (300 MHz, DMSO-d 6 8 (ppm): 1.148 3H), 1.94 2H), 3.46-3.52 4H), 4.53 2H), 4.60 WO 02/17914 WO 0217914PCT/USOI/26266 -41- 2H), 4.73 (in, 211), 4.91 2H), 7.3 6 (in, 3H), 7.48 111), 7.64 (in, 2H1), 7.90 (s, 111), 8.55 1H), 9.47 11U).
Example 2: RW Oine, 95% yield; MS (nilz): 413 435 1H1 NMR (300 MHz, DMSO-d 6 6 (PPM): 1.99 (in, 211), 3.36 3H), 3.54 (in, 2H), 4.58 2H), 4.66 2H), 4.79 (in, 2H1), 4.96 2H1), 7.40-7.49 (in, 2H), 7.52 111), 7.65-7.84 (in, 2H), 7.98 11-1), 8.60 1H), 9.51 111).
Example 3: RW OiPr, 3 1% yield; MS (mlz): 441 TI~ NMR (3 00 MHz, DMSO-d 6 5 (ppim): 1.15 6H, 1.92 (in, 2H), 3.45 (in, 211), 3.67 (in, 111), 4.52 2H), 4.61 211), 4.73 (in, 211), 4,89 211), 7.3-7.39 (in, 2H0, 7.47 1Hf), 7.62-7.69 (in, 2H), 7.89 IH), 8.54 111), 9.47 (di, 111).
Example 4: Wi OCH(C11 3
)CH
2
CH
3 25% yield; MS 455 'H NMR (300 MHz, CDC1 3 8 (ppm): 0.98(t, 3H), 1.26 3H), 1.65 (in, 211), 2.03 (in, 211), 3.56 (in, 2H), 4.095 (mn, 111), 4.24 2H), 4.57 (mn 211), 4.70 (mn, 2H1), 4.71 2H1), 6.12 111), 7.33 111), 7.42- 7.58 (in, 4H), 7.75 111), 9.48 (di, 111).
Example 5: Wi (V-OCH(CH)CH1CH 3 61% yield; MS (mlz): 455 111NMVR (300 MHz, CDCl 3 6 (PPM): 0.98(t, 311), 1.26 311), 1.65 (mn, 211), 2.03 (in, 211), 3.56 (in, 2H), 4.095 (in, 11-1), 4.24 2H), 4.57 (in 2H), 4.70 (mn, 2H), 4.71 211), 6.12 (s, 111), 7.33 1H), 7.42- 7.58 (mn, 4H), 7.75 111), 9.48 111).
Example 6: RW (S)-OCH(G11 3 )C11 2 CH1 3 93% yield; MS 455 1H NMR (300 MHz, CDC1 3 6 (PPM): 0.98(t, 311), 1.26 (di, 311), 1.65 (in, 211), 2.03 (in, 211), 3.56 211), 4.095 (in, 111), 4.24 211), 4.57 (in 2H1), 4.70 (in, 3H), 4.71 21-1), 6.12 (s, 111), 7.33 111), 7.42- 7.58 (in, 411), 7.75 111), 9.48 (di, 111).
Example 8: Wi O-nPr, 62% yield; MS (mlz): 441 462 1 H NMR (300 MHz, DMS0-l 6 6 (PPM): 0.88 311), 1.55 (mn, 211), 1.933 (in, 211), 3.36-3.58 WO 02/17914 WO 0217914PCT/USOI/26266 -42- (in, 4H), 4.53 211), 4.61 211), 4.73 (in, 3H), 4.90 211), 7.3 3-7.39 (mn 2H), 7.47 (d, 111), 7.62-7.70 (in, 2H), 8.54 1Hi), 9.47 1H1).
Example 9: W 5 O-nBu, 92% yield, MS 455 'H NMR (300 MHz, S DMSO-d 6 5 (PPM): 0.854 3R), 1.34 (in, 211), 1.52 (in, 2H), 1.93 (in, 2H), 3.48 (in, 211), 4.52 211), 4.60 211), 4.73 (in, 3H), 4.89 211), 7.30-7.42 (in, 2H1), 7.47 (d, 1H1), 7.62-7.70 (in, 211), 7.89 1H), 8.54 111), 9.47 1H).
Example 17: W 5 O-tBu, 35% yield; MS 455 477 1
HNMR
(300 MHz, DMSO-d 6 8 (ppm): 1.28 9H1), 1.97 (mn, 211), 3.62 (in, 211), 4.56 211), 4.52 2H), 4.77 (in, 3H), 4.94 211), 7.35-7.72 (3m, 311), 7.72 (in, 211), 7.90 111), 8.8S. 57 I 9.5 0 111).
Example 25: R 6 Set, 96% yield; MS (mlz): 443 (M 4 111NMR (300 M11z, DMSOd 6 8 (PPM): 1.17 311), 1.93 (in, 211), 2.42 2H), 3.48 (in, 211), 3.93 211), 4.52 (s, 211), 4.72 (in, 311), 4.89 2H1), 7.33-7.49 (in, 311), 7.65 (in, 211), 7.88 1H), 8.56 (s, 1S I1H), 9.46 111).
Example 26: W 6
SOCH(CH,)
2 MS 494 111NMR (300 M~llz, DMS0d 6 8 (PPM): 1.21 (dd, 611), 1.93 (mn, 2H), 2.82 (mn, 111), 3.49 (in, 211), 4.12 111), 4.23 111), 2.52 211), 4.75 (in, 311), 4.88 211), 7.33-7.45 (in, 211), 7.55 1H1), 7.65 (d, 11H), 7.71 111), 7.94 111), 8.5 8 111), 9.47 111).
Example 27: R 6 SCH(C1 3 2 MS 457 479 'H NMR (300 MF~z, CDCI 3 8 (PPM): 1.31 611), 2.34 (in, 211), 2.86 (in, 111), 3.98 211), 4.29 (s, 211), 4.45 (in, 111), 4.74 (in, 211), 4.92 211), 6.07 1H), 7.39 (mn, 211), 7.51 (mn, 211), 7.57 (mn, 111), 7.80 111), 9.53 111).
Example 37: W 6 nPrS (Trifluoroacetate), 66% yield; 111 NMR (DMSO-d6, 300 MHz): 8 0.92 311), 1.58 2H), 2.29 (in, 211), 2.44 211), 3.95 211), 4.53 (mn, 411), 4.82 WO 02/17914 PCT/US01/26266 -43- 2H), 4.93 2H), 7.41 2H), 7.52 1H), 7.60 1H), 7.72 1H), 7.93 1H), 8.62 1H), 9.51 1H).
Example 38: R 6
S(C
5 H4N), 51% yield; MS (ESI): m/e 514 'HNMR (DMSO-d6, 300 MHz): 6 1.014 2H), 3.45 2H), 4.51 2H), 4.60 2H), 4.72 3H), 4.85 2H), 7.11 1H), 7.30-7.41 3H), 7.54-7.67 4H), 8.02 1H), 8.48 1H, J 3.97), 8.55 1H), 9.46 1H, J 7.36).
Example 39: R 6 S(C4H3N2), 52% yield; MS 493 'HNMR (300 MHz, DMSO-d 6 8 (ppm): 1.93 2H), 3.45 2H), 4.51 3H), 4.60 2H), 4.72 2H), 4.88 2H), 7.22 1H), 7.32-7.68 6H), 8.05 1H), 8.55 s, 1H), 8.66 (d, 1H), 9.46 1H).
Example 30: R 5 H, 44% yield; 'H NMR (300 MHz, DMSO-d 6 8 (ppm): 4.13 2H), 4.64 2H), 4.89 2H), 7.28-7.42 3H), 7.53 1H), 7.64 7.89 1H), 8.49 1H), 9.34 1H), 11.83 1H).
Example 31: R 5 Oet, 83% yield; 'H NMR (300 MHz, DMSO-d 6 6 (ppm): 1.18 (t, 3H), 3.55 2H), 4.62 2H), 4.93 2H), 7.34-7.46 3H), 7.58 1H), 7.68 (d, 1H), 7.92 1H), 8.54 1H), 9.39 1H), 11.91 1H).
Example 32: R 5 OiPr, 41 purified yield; 'H NMR (300 MHz, DMSO-d 6 8 (ppm): 1.15 6H), 3.68 1H), 4.13 2H), 4.59 2H), 4.89 2H), 7.28-7.42 3H), 7.54 1H), 7.64 1H), 7.88 1H), 8.49 1H), 9.35 1H), 11.87 1H).
Preparation of compound XI: To a suspension of aluminum chloride (3 eq.) in 1,2-dichloroethane/ methylene chloride 8 mL) was added acetyl chloride (3 eq.) under nitrogen. The reaction mixture became homogeneous and was cooled to 0 OC in an ice bath. A suspension of B (0.84 mmol, eq.) in methylene chloride (3 mL) was added drop wise and the mixture turned brown in color. The ice bath was removed and the reaction mixture was warmed to room WO 02/17914 PCT/US01/26266 -44temperature. The mixture was heated to reflux for 2h then cooled to room temperature.
HPLC showed no starting material present. The mixture was poured over ice water and cone. HC1 (5 mL) was added. A precipitate formed and was collected by filtration and dried. 340 mg (89 yield), MS 453 'HNMR (300 MHz, DMSO-d 6 6 (ppm): 2.02 3H), 2.18 2H), 2.74 3H), 4.12 2H), 4.56 2H), 4.83 2H), 5.05 2H), 7.43 2H), 7.68 1H), 7.86 1H), 8.17 1H), 8.56 1H), 8.72 9.53 1H).
Example 33: To a suspension of XI (0.18 mmol, 1 eq.) in THF (6 mL) under nitrogen was added lithium borohydride (10 eq.) at 0 The reaction mixture was stirred at 0 °C for 1 h then warmed to room temperature for 4 h. The mixture was cooled to 0 oC and methanol was added slowly drop wise. Vigorous evolution of gas was observed during the quenching of excess borohydride. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo to a white solid, 69 mg (90 yield). MS 413 435 'H NMR (300 MHz, DMSO-d6) 8 (ppm): 1.41 3H), 1.92 2H), 3.46 (mn, 2H), 4.52 (s, 2H), 4.71 3H), 4.89 3H), 5.18 1H), 7.32-7.39 2H), 7.50 1H), 7.64 (m, 7.89 1H), 8.55 1H), 9.46 1H).
The following compounds were prepared according to the general procedure for ether formation using the tri-trifluoroacetate intermediates: Example 10: R 5 Oet, 68 yield; MS 441 395 (M+-OCHCH,); 'H NMR (300 MHz, DMSO-d 6 8 (ppm): 1.08 3H), 1.41 3H), 1.93 2H), 3.47 (m, 2H), 4.52 2H), 4.60 1H), 4.73 2H), 4.90 2H), 7.33-7.39 2H), 7.47 (d, 1H), 7.63 1H), 7.69 1H), 7.86 1H), 8.55 1H), 9.47 1H).
Reverse phase HPLC separation of 10 yielded isomers 11 and 12.
Example 11 (chiral): R Oet, MS 441 395 (M+-OCH 2
CH
3 WO 02/17914 WO 0217914PCT/USOI/26266 Example 12 (chiral): RiOet, MS (mlz) 441 395 (M±-OCH 2
CH,).
Example 13: Wi Omne, 76 yield; MS 427 (M 4 11 NMR (300 MHz, DMSO-d 6 6 (ppmn): 1.45 3H), 1.98 (in, 211), 3.14 3H), 3.50 (in, 211), 4.58 (in, 3H), 7.75 (in, 211), 4.93 2H), 7.33 (in, 2H), 7.48 (di, 111), 7.67 111), 7.72 114), 7.88 111), 8.58 1H4), 9.49 lH).
Example 15: R5 Obu, 73 yield; 1H NMR (3 00 MHz, DMSO-d 6 5 (ppm): 0.-81 (t, 3H), 1.27-1.43 (mn, 711), 1.93 (in, 2H), 3.48 (in, 2H), 4.53 211), 4.58 (in, 1H), 4.73 (in, 4H), 4.92 (in, 2H), 7.33-7.39 (in, 2H1), 7.46 111), 7.63 1H), 7.69 111), 7.86 (s, 1H), 8.55 1H), 9.47 (di, 1H).
Example 16: R 5 OiPr, 63 yield; 'H NMR (300 MHz, DMSO-d 6 5 (ppm): 1.01 (d, 311), 1.10 3H), 1.38 311), 1.95 (in, 211), 3.47 (mn, 211), 3.98 1H1), 4.26 (in, 1H), 4.52 2H), 4.74 311), 4.90 (in, 211), 7.33-7.39 (in, 211), 7.48 1IM, 7.62-7.69 (in, 2H), 7.87 lH), 8.54 lH), 9.47 lH).
Example 35: Wi H, 98 yield; MS (nilz): 455 337 (MW-H 2 'HNMR (300 MHz, DMSO-d 6 8 (ppm): 1.45 311), 4.25 (mn, 311), 4.86 211), 5.16 IHl), 7.28- 7.39 (in, 211), 7.43 111), 7.56 (di, 111), 7.66 111), 7.92 111), 8.49 111), 9.35 (di, 111), 11.78 111).
Example 36: R!i Omne, 50% yield; MS 369 'H NNR (300 MHz, DMSO-1 6 3 (PPM): 1.43 (di, 311), 3.16 311), 4.15 (in, 211), 4.49 (mn, 111), 4.93 21H), 7.32-7.40 (in, 311), 7.58 (di, 111), 7.67 111), 7.84 111), 8.50 111), 9.44 111), 11.87 111).
Exatmple 34: Ri' H, (77 yield over 2 steps); MS 427 (M 4 409 (M 4
-H
2 0); 'H NMR (300 MHz, DMSO-d 6 6 (ppm): 0,848 311), 1.70 (mn, 214), 1.93 211), 3.47 (in, 211), 4.52 211), 4.61 (mn, 111), 4.72 (mn, 311), 4.89 211), 5.14 111), 7.29-7.39 (i,211), 7.44 11),7.64 (in,211),7.87 8.54 (s,114, 9.46 (d,11).
WO 02/17914 PCT/US01/26266 -46- General Procedure for Ester formation of Example 3: An oven dried, 3-L, 3-necked, round-bottomed flask equipped with a mechanical stirrer, a three-way stopcock connected to an argon balloon and an immersion thermometer was charged with compound 3 (148.6 mmol) followed by anhydrous N,N-dimethylacetamide (654 mL). 4- (Dimethylamino)pyridine (DMAP) (0.5 Amino acid (2.5 eq.) and 1-[3- (dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (2.5 eq) were added sequentially at 35 °C to the clear red colored solution. The reaction suspension heated to 42-45 oC for 2 h and additional quantities of DMAP (0.08 Amino Acid (0.5 eq.) and l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.5 eq.) were added sequentially. After 1.5 h, the reaction mixture was cooled to 0-5 oC and quenched with water. The cooling bath was removed and the resulting pale yellow suspension was stirred at room temperature for lh. The suspension was filtered, washed with water to pH= 8 and dried overnight using house vacuum. The pale yellow solid was not dried completely and dissolved in methylene chloride and the water layer was separated. The organic phase was washed with brine, dried over MgSO4, filtered over celite and concentrated using a rotary evaporator to afford the crude solid. The crude material was again dissolved in methylene chloride and transferred into a 3-L, 3-necked roundbottomed flask, which was equipped with a mechanical stirrer. Ethyl acetate (1L) was added drop wise at room temperature to the clear red colored solution for 70 min. with continuous stirring. After the addition of ethyl acetate (15 mL), a precipitate formed.
The slurry was stirred for 2.5 h followed by collection of the solid by filtration. The precipitate was washed sequentially with ethyl acetate, a mixture of ethyl acetate/ methyl-tert butyl ether and methyl t-butyl ether and dried to an off-white solid.
78% yield.
Example 18: MS 498 Example 19: MS 566 (M+1) Example 20: MS 569 (M+l1) Example 21: MS 512 Example 22: MS 554 Example 23: MS 526 (M+Il) Example 24: MS 554 (Ml+1) WO 02/17914 PCT/US01/26266 -47- Preparation of XIII: Example 31 (0.33 mmol) was dissolved in DMF (10 mL) and half the volume was removed by distillation. The flask was cooled to room temperature and sodium hydride (1 eq.) was added and the mixture was stirred for lh. Mesylglycidol (1.5 eq.) was added and the mixture warmed to 50 °C for 24 h then cooled to room temperature. The mixture was filtered and the solvent removed in vacuo. The reaction mixture was purified by column chromatography on silica gel to yield XIII in 73% yield. 1.19 3H), 2.78 (t, 1H), 3.53 4H), 4.53 2H), 4.65 2H), 4.78 (dd, 1H), 4.96 2H), 5.20 1H), 7.35-7.47 2H), 7.51 1H), 7.68 1H), 7.75 1H), 7.95 1H), 8.62 1H), 9.55 1H).
Example 7: Compound XIII (100mg) was dissolved in THF (10 mL) and triethyl borohydride (2mL) was added drop wise. The reaction mixture was heated to 70 oC for 4 h. The mixture was cooled to room temperature and 1N HC1 was added. The solvent was removed in vacuo and the material was taken up in a mixture of methanol/ water.
The resulting precipitate was collected by filtration and dried. 1.19 3H), 1.25 3H), 3.55 2H), 4.13 2H), 4.58 2H), 4.61 2H), 4.64 2H), 4.93 2H), 4.97 (t, 1H), 7.34-7.45 2H), 7.49 1H), 7.69 2H), 7.92 1H), 8.57 1H), 9.50 (d, 1H).
Example 14: To a suspension of XIV (0.75 mmol) in methylene chloride/ methanol/HMPA (4:2:1 mL), was added cesium carbonate (4.0 The reaction mixture was stirred for 30 min. followed by addition of acetaldehyde. Additional acetaldehyde was added with little change observed by TLC. The mixture was diluted with methylene chloride and washed with water and brine. The organic phase was dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude product XV was isolated by column chromatography (33% yield). XV (0.3 mmol) was dissolved in methylene chloride and cooled to 0 Ethanethiol (2 drops) and trifluoroacetic acid (TFA)(1 drop) were added to the solution and the mixture stirred at 0 °C for 1 h. The mixture was warmed to room temperature and stirred for 1 h. Additional TFA (2 drops) was added and the reaction mixture and after 30 minutes the reaction was complete. The WO 02/17914 PCT/US01/26266 -48product was purified by column chromatography on silica gel using methylene chloride/ethyl acetate. A single diastereomer was isolated 65 mg 0.52 3H), 1.21 3H), 2.47 2H), 3.96 2H), 4.49 1H), 4.86 1H), 4.94 2H), 6.18 (s, 1H), 7.35-7.45 3H), 7.64 1H), 7.72 1H), 7.92 1H), 8.57 1H), 9.41 (d, 1H), 10.99 1H).
Preparation of XVII: To a solution of hexamethylenetetraamine (1.6 g, 11.4 mmol) in TFA was added XVI (2.0 g, 4.6 mmol) at 60-65 After stirring 2 hours the reaction was cooled to room temperature, followed by the drop wise addition into 2N H 2 S0 4 acetone (150 mL) The solid was collected, suspended in dioxolane (150 mL) and heated to reflux for 30 minutes. The undissolved material was removed by filtration and the solvent was concentrated to approximately 25 mL. MeOH (50 mL) was added to precipitate the product, which was collected and dried to give 700 mg of an off yellow solid. MS ES' 467 (M 1).
Example 28: A suspension of the XVII (500 mg, 1.1 mmol) in CHC1 3 /methanol (60 mL, 5/1) was added solid NaBH 4 (200mg). The solution was stirred at room temperature for 4 h. The CHC 3 I was removed at reduced pressure followed by the addition of 2 N HC1.
The solution was stirred for 2 h then collected and dried to give 420 mg of an off white solid. MS 469 (M The crude alcohol was suspended in CHC13-MeOH (25 mL 10 mL) then added 0.7 mL of 1 M NaOMe followed by stirring 12 hour at room temperature. The solvent was concentrated, the solid triturated with MeOH and the product collected to give the diol 420 mg 'H NMR (DMSO-d6, 300 MHz): 6 3.8 2 4.55 2H), 4.63 2H), 4.75 2H), 4.97 2H), 5.0, 1H), 5.23 (m, 1H), 7.34-7.51 4H), 7.68 2H), 7.94 1H), 8.57 1H), 9.51 1H). MS (ES) 385 1).
Example 24: A suspension of Example 28 (50 mg, 0.13 mmol) in CHC1 3 was added camphorsulfonic acid (30 mg, 0.26 mmol) and ethane thiol (0.39 mmol), followed by stirring 12 under nitrogen. Excess CHC1, was added and then the solution was washed with 2 M Na 2
CO
3 solution, water, brine and dried (MgSO 4 The solvent was concentrated, and the product collected after triturating with MeOH. 1H NMR (DMSO- WO 02/17914 PCT/US01/26266 -49d6, 300 MHz): 6 1.1, 2.3 2H), 3.85 2H), 4.0 2H), 5.5 21I), 4.8 2H), 4.9 2H), 5.0 1H), 7.35-7.5 4H), 7.7 2H), 8.6 1H), 9.5 1H). 3H), MS 429, 451 (M 1, 23).
Example 40: To a solution of Example 3 (210 mg, 0.48 mmol) in DMF (10 mL) was added DMAP (1 mg), Et 3 N (267 uL, 1.92 mmol) and tBDMSCI (220 mg, 1.47 mmol).
After stirring 20 h, the mixture was taken up in EtOAc and successively washed with aqueous NaHCO 3 water and brine. The organic layer was dried over MgSO 4 filtered and evaporated to afford a residue that was purified by column chromatography (silica gel, 10% EtOAc/hexane) to give 225.1 mg of intermediate XVIII A mixture of XVIII (68.1 mg, 0.10 mmol) and paraformaldehyde (63.1 mg, 2.1 mmol) in pyridine (4 mL) was treated with a 0.25M solution of Triton B in pyridine (100 uL, 0.025 mmol). After stirring for 2 h, additional Triton B in pyridine (150 uL, 0.038 mmol) was added. After 1 h, the mixture was taken up in EtOAc and exhaustively washed with aqueous CuSO4. After washing with water, aqueous NaHCO 3 and brine, the organic layer was dried over MgSO4, filtered and evaporated to afford a residue that was purified by column chromatography (silica gel, 22% EtOAc/hexane) to give 45.2 mg of IXX which had the following spectral properties: 'H NMR (DMSO-d 6 6 9.42 1H, J 7.97 1H), 7.75 7.72 2H), 7.52 1H, J 7.44 (dd, 1H, J 7.7, 7.36 (dd, 1H, J 7.7, 5.13 1H), 5.04 2H), 4.77 (m1, 1H), 4.70 2H), 4.10 1H), 3.76 (sep, 1H, J= 3.54 1H), 3.44 1H), 3.31 3H), 1.79 2H), 1.22 6H), 1.07 9H), 0.85 9H), 0.52 6H), 0.00 3H), -0.03 3H); MS m/z 699 To a solution of XXI (22.5 mg, 0.032 mrnol) in iPrOH (10 mL) was added TMSC1 (100 uL), and the mixture was stirred for 2.5 h. After evaporation of solvent, the residue was triturated with ether (3 x ImL) and dried to afford 10.8 mg of Example 40 which had the following spectral properties: 'H NMR (DMSO-d 6 9.49 1H, J 8.59 (s, 1H), 7.96 1H), 7.80 1H, J 7.77 1H, J 8.5) 7.55 1H, J 7.45 1H), 7.37 1H), 4.98 3H), 4.78 2H), 4.70 2H), 4.20 4.16 2H), 3.76 (sep, 1H, J 3.38 1H), 3.36 3.25 2H), 1.80 2H), 1.23 6H, J= MS m/z 471 WO 02/17914 PCT/US01/26266 Inhibition of Vascular Endothelial Growth Factor Receptor Kinase Activity Fused pyrrolocarbazole compounds were examined for their inhibitory effects on the kinase activity of baculovirus-expressed VEGF receptor (human flk-1, KDR, VEGFR2) kinase domain using the procedure described for the trkA kinase ELISA assay described below. The kinase reaction mixture, consisting of 50 mM Hepes, pH 7.4, |tM ATP, 10 mM MnC1 2 0.1% BSA, 2% DMSO, and various concentrations of inhibitor, was transferred to PLC-y/GST-coated plates. VEGFR kinase was added and the reaction was allowed to proceed for 15 min. at 37°C. Detection of phosphorylated product was accomplished by addition of anti-phosphotyrosine antibody (UBI). A secondary enzyme-conjugated antibody was delivered to capture the antibodyphosphorylated PLC-y/GST complex. The activity of the bound enzyme was measured via an amplified detection system (Gibco-BRL). Inhibition data were analyzed using the sigmoidal dose-response (variable slope) equation in GraphPad Prism. Results are summarized in Table III.
Table III: VEGFR Inhibition Compound VEGFR2 (ICso or inh. 300 nM) A 107 B 48 C 17% D 200 1 4 2 17 3 7 4 12 12 6 19 WO 02/17914 WO 0217914PCT/USOI/26266 Compound VEG1FR2 or inh. @300 nM) 7 8 13 9 18 83 11 12 240 13 73 14 72 130 16 411 17 11 18 23 19 31 2148 22 1 2357 2431 2 26 31% 27 57 28 34% 29 208 302 31 77 32 33% 33 I11 34 7 WO 02/17914 PCT/US01/26266 Compound VEGFR2 (ICso or inh. 300 nM) 37% 36 12% 37 37% 38 39 13% 16 Inhibition of Mixed Lineage Kinase-1 (MLK1) Activity The kinase activity of MLK1 was assessed using the Millipore Multiscreen TCA "in-plate" format as described for protein kinase C (Pitt Lee, J. Biomol. Screening, 1: 47-51, 1996). Briefly, each 50-pl assay mixture contained 20 mM Hepes, pH 7.2, 5 mM EGTA, 15 mM MgC12, 25 mM p-glycerophosphate, 60 pM ATP, 0.25 pCi [y- 3 2
P]ATP,
0.1% BSA, 500 pg/ml myelin basic protein (UBI #13-104), 2% DMSO, 1 p M of test compound, and 1 pg/ml ofbaculoviral GST-MLK1I. Samples were incubated for min at 37°C. The reaction was stopped by adding ice cold 50% TCA and the proteins were allowed to precipitate for 30 min at 4 0 C. The plates were then washed with ice cold 25% TCA. Supermix scintillation cocktail was added, and the plates were allowed to equilibrate for 1-2 hours prior to counting using the Wallac MicroBeta 1450 PLUS scintillation counter.
Inhibition of Mixed Lineage Kinase-2 (MLK2) Activity Assays were performed using the Millipore Multiscreen plate format as described for MLK1. Each 50-p1 assay mixture contained 20 mM Hepes, pH 7.2, 5 mM EGTA, mM MgCl 2 25 mM p-glycerophosphate, 100 pLM ATP, 0.25 jiCi [y- 2 P]ATP, 0.1% BSA, 500 p-g/ml myelin basic protein (UBI #13-104), 2% DMSO, various concentrations of test compound, and 3 pg/ml ofbaculoviral GST-MLK2KDLz. Samples were incubated for min. at 37 0 C. The reaction was stopped by adding ice cold 50% TCA and the proteins were allowed to precipitate for 30 min at 4 0 C. The plates were then washed WO 02/17914 PCT/US01/26266 -53with ice cold 25% TCA. Supermix scintillation cocktail was added, and the plates were allowed to equilibrate for 1-2 hours prior to counting.
Inhibition of Mixed Lineage Kinase-3 (MLK3) Activity Assays were performed using the Millipore Multiscreen plate format as described for MLK1. Briefly, each 50-pl assay mixture contained 20 mM Hepes, pH 7.2, 5 mM EGTA, 15 mM MgC1 2 25 mM P-glycerophosphate, 100 tM ATP, 0.25 tLCi [y- 3 2
P]ATP,
0.1% BSA, 500 g/ml myelin basic protein (UBI #13-104), 2% DMSO, various concentrations of test compound, and 2 jig/ml ofbaculoviral GST-MLK3. Samples were incubated for 15 min at 37°C. The reaction was stopped by adding ice cold TCA and the proteins were allowed to precipitate for 30 min at 4°C. The plates were then washed with ice cold 25% TCA. Supermix scintillation cocktail was added, and the plates were allowed to equilibrate for 1-2 hours prior to counting.
TABLE IV: MLK Inhibition IC50 (nM) or Inhibition 100 Compound MLK1 MLK2 MLK3 A 22 39% 8 B 31 46% 17 C 8% 0% D 45 43% 1 21 4 2 15 8 3 17 9 4 15 4 WO 02/17914 WO 0217914PCT/US01/26266 27 45% 16 6 38 51% 19 7 85% 8 19 76% 13 9 26 37 11 78 12 28 131 16 13 20 62% 26 14 93% 9 41 27 16 66% 49% 17 35 18 47 23 19 44% 28% 42 229 32 21 22 74 170 28 23 31% 24 62% 22 12 26 59 27 22 WO 02/17914 PCT/US01/26266 28 76 74 29 9 64% 31 46 29 32 24 19 33 50 16 34 45% 32% 60% 62% 36 26 41% 37 17 38 58% 39 55% 56% 21 86 Inhibition of trkA Tyrosine Kinase Activity Selected isomeric fused pyrrolocarbazole and isoindolone compounds can be tested for their ability to inhibit the kinase activity of baculovirus-expressed human trkA cytoplasmic domain using an ELISA-based assay as previously described (Angeles et al., Anal. Biochem. 236: 49-55, 1996). Briefly, the 96-well microtiter plate is coated with substrate solution (recombinant human phospholipase C- yl/glutathione S-transferase fusion protein (Rotin et al., EMBO 11: 559-567, 1992). Inhibition studies are performed in 100 pl assay mixtures containing 50 mM Hepes, pH 7.4, 40jLM ATP, mM MnCl1, 0.1% BSA, 2% DMSO, and various concentrations of inhibitor. The reaction is initiated by addition oftrkA kinase and allowed to proceed for 15 minutes at 37 0 C. An antibody to phosphotyrosine (UBI) is then added, followed by a secondary enzyme-conjugated antibody, alkaline phosphatase-labelled goat anti-mouse IgG (Bio- Rad). The activity of the bound enzyme is measured via an amplified detection system WO 02/17914 PCT/US01/26266 -56- (Gibco-BRL). Inhibition data are analyzed using the sigmoidal dose-response (variable slope) equation in GraphPad Prism. The concentration that resulted in 50% inhibition of Idnase activity is referred to as "IC 5 o".
Inhibition of NGF-stimulated trk Phosphorylation in a Whole Cell Preparation The inhibition of NGF-stimulated phosphorylation of trk by the compounds of the present invention can be performed using a modified procedure, as described below, from that previously described (see US Patent No. 5,516,771). NIH3T3 cells transfected with trkA are grown in 100 mm dishes. Subconfluent cells are serum-starved by replacing media with serum-free 0.05% BSA-DMEM containing compound (100 nM and 1 OM) or DMSO (added to controls) for one hour at 37 0 C. NGF (Harlan/Bioproducts for Science) is then added to the cells at a concentration of 10 ng/ml for 5 minutes. Cells are lysed in buffer containing detergent and protease inhibitors. Clarified cell lysates are normalized to protein using BCA method and irmnunoprecipitated with anti-trk antibody.
Polyclonal anti-trk antibody is prepared against a peptide corresponding to the 14 amino acids at the carboxy terminus of trk (Martin-Zanca et al., Mol. Cell. Biol. 9: 24-33, 1989).
The immune complexes are collected on Protein A Sepharose beads (Sigma Chem. Co., St. Lois, MO), separated by SDS polyacrylamide gel electrophoresis (SDS- PAGE), and transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane is immunoblotted with anti-phosphotyrosine antibody (UBI), followed by incubation with horseradish peroxidase coupled goat anti-mouse IgG (Bio-Rad Laboratories, Hercules, CA). Phosphorylated proteins were visualized using ECL (Amersham Life Science, Inc., Arlington Heights, IL). The area of the trk protein band is measured and compared to NGF-stimulated control. The inhibition scoring system used, based on percent decrease in trk protein band, can be as follows: 0 no decrease; 1 1- 2 26-49%; 3 50-75%; 4 76-100%.
Inhibition of Platelet Derived Growth Factor Receptor Kinase Activity Isomeric fused pyrrolocarbazole and isoindolone compounds can examined for their inhibitory effects on the kinase activity ofbaculovirus-expressed PDGF receptor WO 02/17914 PCT/US01/26266 -57kinase domain using the trkA kinase ELISA described above. Assays are performed in substrate (PLC-y/GST)-coated 96-well microtiter plates. Each 100-1p reaction mixture contains 50 mM HEPES, pH 7.4, 20M ATP, 10 mM MnC12, 0.1% BSA, 2% DMSO, and various concentrations of inhibitor. The reaction is initiated by addition of prephosphorylated recombinant human enzyme (10 ng/ml PDGFRp) and allowed to proceed for 15 minutes at 37 The prephosphorylated enzyme is prepared prior to use by incubation of the kinase in buffer containing 20 iM ATP and 10 mM MnCl 2 for 1 hour at 4 C. Detection of phosphorylated product is done by adding horseradish peroxidase (HRP)-conjugated anti-phosphotyrosine antibody (UBI). The HRP substrate S0 solution containing 3, 5'-tetramethylbenzidine and hydrogen peroxide is later added and the plates incubated for 10 minutes at room temperature. The reaction is quenched with acid and the resulting absorbance is read at 450 nm using a Microplate Bio-kinetics Reader (Bio-Tek Instrument EL 312e). Inhibition data are analyzed using the sigmoidal dose-response (variable slope) equation in GraphPad Prism.
Although the present invention has been described in considerable detail, those skilled in the art will appreciate that numerous changes and modifications may be made to the embodiments and preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all equivalent variations as fall within the scope of the invention.
Claims (34)
1. A compound of Formula I: H 00 R i R R 2 Formula I wherein: R' and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2; with the proviso that when R 1 is (CH 2 3 0H and R 2 is H, then R 3 cannot be -CH 2 OH, -CH 2 0CH 2 CH 3 or -CH 2 SCH 2 CH 3 N 2. A compound of Formula II: T H 0 N R R 2 C Formula II wherein: R' and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2; with the proviso that when R' is (CH 2 3 0H and R 2 is H, then R 3 cannot be -CH 2 0H, -CH 2 0CH 2 CH 3 or -CH 2 SCH 2 CH 3
3. A compound of claim 1 or 2 wherein: R' is an alkyl of 1-4 carbons, substituted with -OH or -OR 4 where R 4 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; R 2 is H; and R 3 is alkyl of 1-4 carbons, substituted with -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; and R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed.
4. A compound of claim 1 or 2 wherein: R 1 is -CH 2 CH 2 CH 2 OH or -CH 2 CH 2 CH 2 OGOCH 2 N(0H 3 2 R 2 is H; and R 3 is -CH 2 0R 7 wherein R 7 is alkyl of 1-4 carbons. A compound of any one of claims 1, 2 or 4, excluding compounds wherein: R 1 is CH 2 CH 2 CH 2 OH; R 2 is H; and R 3 is CH 2 00H(CH 3 2
6. A compound of claim 1 or 2 selected from the group represented in Table Table I Cmpd R 2R 2 CH 2 CH 2 CH 2 OH H 0H 2 00H 3 4 CH 2 CH 2 CH 2 OH H CH 2 00H(CH 3 )CH 2 CH 3 2 CH 2 CH 2 OH H (S)-CH 2 0CH(CH 3 )CH 2 CH 3 6 CH 2 CH 2 CH 2 OH H (R)-CH 2 0CH(CH 3 )CH 2 CH 3 7 CH 2 CHOHCH 3 H CH 2 0CH 2 CH 3 8 CH 2 CH 2 CH 2 OH H CH 2 0CH 2 CH 2 CH 3 9 CH 2 CH 2 CH 2 OH H CH 2 0CH 2 CH 2 CH 2 CH 3 CH 2 CH 2 CH 2 OH H CH(CH 3 )OCH 2 CH 3 Cmpd R 2R 11 CH 2 CH 2 CH 2 OH H (chiral) CH(CH 3 )OCH 2 CH 3 12 CH 2 CH 2 CH 2 OH H (chiral) CH(CH 3 )OCH 2 CH 3 13 CH 2 CH 2 CH 2 OH H CH(0H 3 )00H 3 14 H CH 2 CHOHCH 3 CH 2 OCH 2 CH 3 CH 2 CH 2 CH 2 OH H CH(CH 3 )OCH 2 CH 2 CH 2 CH 3 16 CH 2 CH 2 CH 2 OH H CH(CH 3 )OCH(CH 3 2 17 CH 2 CH 2 CH 2 OH H CH- 2 00(CH 3 3 18 CH 2 CH 2 CH 2 0000H 2 NH 2 H CH 2 00H(CH 3 2 19 C222C(NH 2 H CH 2 00H(CH 3 2 0H 2 -CH 2 CH 2 CH 2 NH 2 CH 2 CH 2 CH 2 0000H 2 CH 2 H CH 2 00H(CH 3 2 NH- 2 21 CH 2 CH 2 CH 2 0000H 2 CH 2 H CH 2 00H(CH 3 2 CH 2 N(CH 3 2 22 C222C2(C H CH 2 00H(CH 3 2 H 3 2 23 C222CC2C2 H CH 2 00H(CH 3 2 CH 2 -CH 2 CH 2 NH 2 24 CH 2 CH 2 OH H CH 2 SCH 2 CH 3 26 CH 2 CH 2 CH 2 OH H CH 2 S(O)CH(CH 3 2 27 CH 2 CH 2 CH 2 OH H CH 2 SCH(CH 3 2 28 CH 2 CH 2 OH H CH 2 0H H H CH 2 0H 31 H H CH 2 00H 2 CH 3 32 H H CH 2 00H(CH 3 2 33 CH 2 CH 2 CH 2 OH H CH(OH)CH 3 34 CH 2 CH9CH9OH H CH(OH)CH 2 CH 3 a) C4 Cc, Cmpd R1 R2 R 3 H H CH(OH)CH 3 36 H H CH(OCH 3 )CH 3 CH 2 CH 2 CH 2 0H CH20H CH 2 0CH(CH 3 2
7. A compound of claim 1 or 2 further selected from the group represented in Table II: Table II
8. A pharmaceutical composition comprising a compound of any one of claims 1 to 5 and a pharmaceutically acceptable excipient or carrier.
9. A method for treating prostate disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I: Formula I wherein: R' and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and 0 R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of N 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and Ca wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; SR 8 is the residue of an amino acid after the hydroxyl group of the carboxyl I n group is removed; 00 c n is an integer of 1-4; and yis 1 or 2. The method of claim 9, excluding compounds wherein: R 1 is CH 2 CH 2 CH 2 0H; R 2 is H; and R 3 is CH 2 0CH(CH 3 2
11. The method of claim 9 or 10, wherein the prostate disorder is prostate cancer or benign prostate hyperplasia.
12. A method for treating angiogenic disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I: Formula I wherein: 0 R 1 and R 2 are the same or different and are independently selected from C H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- cu 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the c carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and Swherein In R 5 is alkyl of 1-4 carbons or aryl; 00 C R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; SR 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2.
13. The method of claim 12, excluding compounds wherein:: R' is CH 2 CH 2 CH 2 0H; R 2 is H; and R 3 is CH 2 0CH(CH 3 2
14. The method of claim 12 or 13, wherein the angiogenic disorder is cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma. A method for treating pathological disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I: R3-- R R In Formula I 00 0wherein: cN R 1 and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 OR 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and yis 1 or 2.
16. The method of claim 15, excluding compounds wherein:: R' is CH 2 CH 2 CH 2 0H; R 2 is H; and R 3 is CH 2 0CH(CH 3 2
17. The method of claim 15 or 16, wherein the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis. O 18. A method for treating neurodegenerative diseases and disorders, C Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, CD ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, Speripheral neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral neuropathy or injuries of the brain or spinal chord which comprises administering to a host in need of such treatment a therapeutically effective Samount of a compound of Formula I: oo SH OO (N R3 N R R 2 Formula I wherein: R' and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR 5 -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2. 0 19. The method of claim 18, excluding compounds wherein: N R 1 is CH 2 CH 2 CH 2 0H; D R 2 is H; and R 3 is CH 2 0CH(CH 3 2
20. A method for treating multiple myeloma and leukemias which comprises 0administering to a host in need of such treatment a therapeutically effective I amount of a compound of Formula I: 00 H NO R R 2 Formula I wherein: R 1 and R 2 are the same or different and are independently selected from H, or alkyl of 1-8 carbons, substituted with -OH, or -OR 4 where R 4 is an alkyl of 1- 4 carbons, aryl or the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; and R 3 is -CH 2 0H; -CH 2 0R 7 -(CH 2 )nSR; -(CH 2 )nS(O)yR 5 -CH 2 SR 5 or alkyl of 1-8 carbons substituted with -OH, -OR 5 -OR 8 -CH 2 0R 7 -S(O)yR 6 or -SR 6 and wherein R 5 is alkyl of 1-4 carbons or aryl; R 6 is H, alkyl of 1-4 carbons or aryl of 6-10 carbons; R 7 is H or alkyl of 1-4 carbons; R 8 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; n is an integer of 1-4; and y is 1 or 2. O 21. The method of claim 20, excluding compounds wherein: NC R 1 is CH 2 CH 2 CH 2 0H; D R 2 is H; and R 3 is CH 2 0CH(CH 3 2
22. The method of claim 20 or 21, wherein the leukemia is acute myelogenous 0leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, or chronic n lymphocytic leukemia. 00
023. A compound of claim 2 wherein R 1 is (CH 2 3 0H, R 2 is H, and R 3 is CN CH 2 0CH(CH 3 2
24. A compound of claim 2 wherein R 1 is (CH 2 3 0COCH 2 N(CH 3 2 R 2 is H, and R 3 is CH 2 0CH(CH 3 2 A pharmaceutical composition comprising a compound of claim 23.
26. A pharmaceutical composition comprising a compound of claim 24.
27. A method for treating or preventing prostate disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of claim 23 or 24.
28. The method of claim 27, wherein the prostate disorder is prostate cancer or benign prostate hyperplasia.
29. A method for treating or preventing angiogenic disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of claim 23 or 24. The method of claim 29, wherein the angiogenic disorder is cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma. O 31. A method for treating or preventing pathological disorders which comprises c- administering to a host in need of such treatment or prevention a therapeutically a, effective amount of a compound of claim 23 or 24. Cc,
32. The method of claim 31, wherein the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal 0wound healing, atherosclerosis, or restenosis. 00 c 33. A method for treating or preventing neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's c disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral neuropathy or injuries of the brain or spinal chord which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of claim 23 or 24.
34. A method for treating or preventing multiple myeloma and leukemias which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of claim 23 or 24. The method of claim 34, wherein the leukemia is acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia.
36. A compound of formula II selected from the group represented in the following table: c Cmpd R1 R2 R 3 37 CH 2 CH 2 CH 2 0COCF 3 H CH 2 SCH 2 CH 2 CH 3 cn 39 CH 2 CH 2 CH 2 0H H CH 2 S(2-pyrimidyl) cI 37. Use of a compound of formula I as claimed in any one of claims 1 or 3 to 6 0o for the preparation of a medicament for the treatment of prostate disorders. 0 5 38. Use of a compound of formula II as claimed in any one of claims 2 to 6, 23, 24 or 36, for the preparation of a medicament for the treatment of prostate disorders.
39. The use according to claim 37 or 38, wherein the medicament is for the treatment of prostate cancer or benign prostate hyperplasia.
40. The use according to claim 37 or 38, wherein the medicament is for the treatment of angiogenic disorders.
41. The use according to claim 40, wherein the medicament is for the treatment of cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma.
42. The use according to claim 37 or 38, wherein the medicament is for the treatment of pathological disorders.
43. The use according to claim 42, wherein the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal would healing, atherosclerosis, or restenosis.
44. The use according to claim 37 or 38, wherein the medicament is for the treatment of neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, O Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral cI neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral a, neuropathy or injuries of the brain or spinal chord. Cc, The use according to claim 37 or 38, wherein the medicament is for the treatment of multiple myeloma and leukemias. N 46. The use according to claim 45, wherein the leukemia is acute oo c myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic 0 leukemia, or chronic lymphocytic leukemia.
47. A compound substantially as hereinbefore described with reference to the accompanying examples.
48. A pharmaceutical composition substantially as hereinbefore described with reference to the accompanying examples.
49. A method substantially as hereinbefore described with reference to the accompanying examples.
50. The use substantially as hereinbefore described with reference to the accompanying examples. CEPHALON, INC. WATERMARK PATENT TRADE MARK ATTORNEYS 302 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P22498AU00 CJH/RLS
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22780300P | 2000-08-25 | 2000-08-25 | |
US60/227,803 | 2000-08-25 | ||
US27845501P | 2001-03-23 | 2001-03-23 | |
US60/278,455 | 2001-03-23 | ||
US09/935,285 | 2001-08-22 | ||
PCT/US2001/026266 WO2002017914A2 (en) | 2000-08-25 | 2001-08-23 | Fused pyrrolocarbazoles against inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001285205A1 AU2001285205A1 (en) | 2002-06-06 |
AU2001285205B2 true AU2001285205B2 (en) | 2007-03-01 |
Family
ID=38134656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001285205A Ceased AU2001285205B2 (en) | 2000-08-25 | 2001-08-23 | Fused pyrrolocarbazoles against inflammation |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2001285205B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
-
2001
- 2001-08-23 AU AU2001285205A patent/AU2001285205B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6630500B2 (en) | Selected fused pyrrolocarbazoles | |
EP1083903B1 (en) | Bridged indenopyrrolocarbazoles | |
JP5006046B2 (en) | Novel condensed pyrrolocarbazole | |
EP2797921A1 (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
EA013182B1 (en) | Novel fused pyrrolocarbazoles | |
KR20060098368A (en) | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | |
AU2001285205B2 (en) | Fused pyrrolocarbazoles against inflammation | |
AU2001285205A1 (en) | Fused pyrrolocarbazoles against inflammation | |
TWI633107B (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
EP4378943A1 (en) | 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof | |
JP2009519954A (en) | Dimers and adducts of 6-[(substituted) phenyl] triazolopyrimidines useful as anticancer agents | |
ZA200301439B (en) | Fused pyrrolocarbazoles against inflammation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |